161 related articles for article (PubMed ID: 19509250)
1. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin.
Zhou Q; Yan B; Hu X; Li XB; Zhang J; Fang J
Mol Cancer Ther; 2009 Jun; 8(6):1684-91. PubMed ID: 19509250
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
3. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
Fang J; Zhou Q; Shi XL; Jiang BH
Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
[TBL] [Abstract][Full Text] [Related]
4. Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo.
Lu X; Yan C; Huang Y; Shi D; Fu Z; Qiu J; Yin Y
Oncotarget; 2016 Jun; 7(24):37177-37191. PubMed ID: 27184007
[TBL] [Abstract][Full Text] [Related]
5. SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin.
Deep G; Jain AK; Ramteke A; Ting H; Vijendra KC; Gangar SC; Agarwal C; Agarwal R
Mol Cancer; 2014 Feb; 13():37. PubMed ID: 24565133
[TBL] [Abstract][Full Text] [Related]
6. Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
Lu J; Li G; He K; Jiang W; Xu C; Li Z; Wang H; Wang W; Wang H; Teng X; Teng L
J Transl Med; 2015 Feb; 13():42. PubMed ID: 25638174
[TBL] [Abstract][Full Text] [Related]
7. Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells.
Kim CJ; Sakamoto K; Tambe Y; Inoue H
Int J Oncol; 2011 Jun; 38(6):1759-66. PubMed ID: 21468544
[TBL] [Abstract][Full Text] [Related]
8. Effect of Slug-Mediated Down-Regulation of E-Cadherin on Invasiveness and Metastasis of Anaplastic Thyroid Cancer Cells.
Sheng L; Zhang S; Xu H
Med Sci Monit; 2017 Jan; 23():138-143. PubMed ID: 28070118
[TBL] [Abstract][Full Text] [Related]
9. Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo.
Zhou R; Lu Z; Liu K; Guo J; Liu J; Zhou Y; Yang J; Mi M; Xu H
Curr Cancer Drug Targets; 2015; 14(9):860-71. PubMed ID: 25431082
[TBL] [Abstract][Full Text] [Related]
10. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
11. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
12. MTBP Promotes the Invasion and Metastasis of Hepatocellular Carcinoma by Enhancing the MDM2-Mediated Degradation of E-Cadherin.
Lu S; Zhou W; Wei H; He L; Li L
Dig Dis Sci; 2015 Dec; 60(12):3681-90. PubMed ID: 26280083
[TBL] [Abstract][Full Text] [Related]
13. Synergistic suppression of prostatic cancer cells by coexpression of both murine double minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo.
Ji K; Wang B; Shao YT; Zhang L; Liu YN; Shao C; Li XJ; Li X; Hu JD; Zhao XJ; Xu DQ; Li Y; Cai L
J Pharmacol Exp Ther; 2011 Jul; 338(1):173-83. PubMed ID: 21444629
[TBL] [Abstract][Full Text] [Related]
14. PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.
Barber AG; Castillo-Martin M; Bonal DM; Jia AJ; Rybicki BA; Christiano AM; Cordon-Cardo C
Cancer Med; 2015 Aug; 4(8):1258-71. PubMed ID: 26033689
[TBL] [Abstract][Full Text] [Related]
15. Luteolin reduces the invasive potential of malignant melanoma cells by targeting β3 integrin and the epithelial-mesenchymal transition.
Ruan JS; Liu YP; Zhang L; Yan LG; Fan FT; Shen CS; Wang AY; Zheng SZ; Wang SM; Lu Y
Acta Pharmacol Sin; 2012 Oct; 33(10):1325-31. PubMed ID: 22983392
[TBL] [Abstract][Full Text] [Related]
16. IQGAP2, A candidate tumour suppressor of prostate tumorigenesis.
Xie Y; Yan J; Cutz JC; Rybak AP; He L; Wei F; Kapoor A; Schmidt VA; Tao L; Tang D
Biochim Biophys Acta; 2012 Jun; 1822(6):875-84. PubMed ID: 22406297
[TBL] [Abstract][Full Text] [Related]
17. Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4.
Tian L; Shen D; Li X; Shan X; Wang X; Yan Q; Liu J
Oncotarget; 2016 Jan; 7(2):1619-32. PubMed ID: 26636541
[TBL] [Abstract][Full Text] [Related]
18. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression.
Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H
Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422
[TBL] [Abstract][Full Text] [Related]
19. microRNA-203 suppresses invasion of gastric cancer cells by targeting ERK1/2/Slug/ E-cadherin signaling.
Gao P; Wang S; Jing F; Zhan J; Wang Y
Cancer Biomark; 2017; 19(1):11-20. PubMed ID: 28269747
[TBL] [Abstract][Full Text] [Related]
20. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.
Li M; Zhang Z; Hill DL; Wang H; Zhang R
Cancer Res; 2007 Mar; 67(5):1988-96. PubMed ID: 17332326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
